Affordable Access

deepdyve-link
Publisher Website

Development of extended-release solid dispersion granules of tacrolimus: evaluation of release mechanism and human oral bioavailability.

Authors
  • Tsunashima, Daisuke1, 2
  • Yamashita, Kazunari1
  • Ogawara, Ken-Ichi2
  • Sako, Kazuhiro3
  • Hakomori, Tadashi1
  • Higaki, Kazutaka2
  • 1 Pharmaceutical Research and Technology Labs., Astellas Pharma Inc., Yaizu, Shizuoka, Japan. , (Japan)
  • 2 Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, Kita-ku, Okayama, Japan. , (Japan)
  • 3 Astellas Ireland Co., Ltd., Damastown Road, Damstown Industrial Park, Mulhuddart, Dublin 15, Ireland. , (Ireland)
Type
Published Article
Journal
The Journal of pharmacy and pharmacology
Publication Date
Dec 01, 2017
Volume
69
Issue
12
Pages
1697–1706
Identifiers
DOI: 10.1111/jphp.12804
PMID: 28872687
Source
Medline
Keywords
License
Unknown

Abstract

We successfully developed the formulation exhibiting a significant reduction in Cmax , the longer mean residence time and AUC close to that of an immediate-release tacrolimus formulation, being preferred from the viewpoint of safe and effective immunosuppressant pharmacotherapy.

Report this publication

Statistics

Seen <100 times